BridgeBio Pharma, Inc.
encaleret
chronic hypoparathyroidism
Resolved
7days ago
Phase 3 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 3 trial results for encaleret in chronic hypoparathyroidism are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“CALIBRATE, the Phase 3 clinical trial of encaleret in ADH1, successfully achieved all pre-specified primary and key secondary efficacy endpoints.”